Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Simepdekinra

Alternative Names: Simepdekinra, LY-4100511, LY4100511, LY 4100511, DC-853, DC853, DC 853
Latest Update: 2025-02-24
Latest Update Note: Clinical Trial Update

Product Description

DC-853 is a differentiated fast follower molecule of DC 806 with improved potency and metabolic stability to support projected therapeutic benefit at lower doses DC-853 entering GLP safety studies; Phase 1 trials results anticipated 2023. (Sourced from: https://sec.report/Document/0001193125-22-044809/)

Mechanisms of Action: IL17 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Simepdekinra

Countries in Clinic: Czech Republic, Germany, Hungary, Poland, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 2: Psoriasis

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2031240450

P2

Not yet recruiting

Psoriasis

2025-12-31

J5C-MC-FOAB

P2

Unknown Status

Psoriasis

2025-11-01

J5C-MC-FOAB

P2

Recruiting

Psoriasis

2025-07-01

J5C-MC-FOAF, DC-853104

P1

Completed

Healthy Volunteers

2024-12-31

Recent News Events

Date

Type

Title

06/20/2023

News Article

 Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

03/01/2023

News Article

 DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

10/11/2022

News Article

 DICE Announces Proposed Public Offering of Common Stock

10/11/2022

News Article

 DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions